Alpha 2.0
Login Register
» Authors » Rafal Wierzbicki

Rafal Wierzbicki

Explore the profile of Rafal Wierzbicki including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 13
Citations 1361
Followers 0
Related Specialties
Oncology
Pulmonary Medicine
General Medicine
Top 10 Co-Authors
Francesco Perrone
Alessandro Morabito
Natasha B Leighl
Kristian Molhave
Paolo Maione
Saverio Cinieri
Derek J Jonker
Peter M Ellis
Normand Blais
Floriana Morgillo
Published In
J Clin Oncol
J Thorac Oncol
Sensors (Basel)
Clin Lung Cancer
N Engl J Med
Affiliations
Soon will be listed here.
Recent Articles
1.
A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Non-Small-Cell Lung Cancer
Ellis P, Leighl N, Hirsh V, Reaume M, Blais N, Wierzbicki R, et al.
Clin Lung Cancer . 2015 Jun; 16(6):457-65. PMID: 26100229
Unlabelled: Second-line therapy options that improve survival for patients with advanced non-small-cell lung cancer (NSCLC) are needed. This randomized, phase II trial (n [ 143) investigated volasertib monotherapy or in...
2.
Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial
Ellis P, Shepherd F, Millward M, Perrone F, Seymour L, Liu G, et al.
Lancet Oncol . 2014 Dec; 15(12):1379-88. PMID: 25439692
Background: Dacomitinib is an irreversible pan-HER tyrosine-kinase inhibitor with preclinical and clinical evidence of activity in non-small-cell lung cancer. We designed BR.26 to assess whether dacomitinib improved overall survival in...
3.
A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced non-small-cell lung cancer
Paz-Ares L, Balint B, De Boer R, van Meerbeeck J, Wierzbicki R, de Souza P, et al.
J Thorac Oncol . 2013 Feb; 8(3):329-37. PMID: 23370314
Introduction: This study evaluated the efficacy, safety, and pharmacokinetics of conatumumab combined with paclitaxel-carboplatin (PC) as first-line treatment for advanced non-small-cell lung cancer (NSCLC). Methods: Patients (aged >18 years) with...
4.
Mapping the complex morphology of cell interactions with nanowire substrates using FIB-SEM
Wierzbicki R, Kobler C, Jensen M, Lopacinska J, Schmidt M, Skolimowski M, et al.
PLoS One . 2013 Jan; 8(1):e53307. PMID: 23326412
Using high resolution focused ion beam scanning electron microscopy (FIB-SEM) we study the details of cell-nanostructure interactions using serial block face imaging. 3T3 Fibroblast cellular monolayers are cultured on flat...
5.
Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer
Di Maio M, Leighl N, Gallo C, Feld R, Ciardiello F, Butts C, et al.
J Thorac Oncol . 2012 Nov; 7(12):1830-1844. PMID: 23154555
Introduction: The TORCH (Tarceva or Chemotherapy) trial randomized patients with advanced non-small-cell lung cancer to first-line erlotinib followed by second-line cisplatin/gemcitabine versus. standard inverse sequence. The trial, designed to test...
6.
First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial
Gridelli C, Ciardiello F, Gallo C, Feld R, Butts C, Gebbia V, et al.
J Clin Oncol . 2012 Jul; 30(24):3002-11. PMID: 22778317
Purpose: Erlotinib prolonged survival of unselected patients with advanced non-small-cell lung cancer (NSCLC) who were not eligible for further chemotherapy, and two phase II studies suggested it might be an...
7.
Can a computerized format replace a paper form in PRO and HRQL evaluation? Psychometric testing of the computer-assisted LCSS instrument (eLCSS-QL)
Hollen P, Gralla R, Stewart J, Meharchand J, Wierzbicki R, Leighl N
Support Care Cancer . 2012 Jun; 21(1):165-72. PMID: 22684988
Purpose: This trial assessed the ability to enhance health-related quality of life (HRQL) and patient-reported outcome (PRO) evaluation in trials and patient management using computer assistance with a handheld device,...
8.
Cell motility, morphology, viability and proliferation in response to nanotopography on silicon black
Lopacinska J, Gradinaru C, Wierzbicki R, Kobler C, Schmidt M, Madsen M, et al.
Nanoscale . 2012 May; 4(12):3739-45. PMID: 22614757
Knowledge of cells' interactions with nanostructured materials is fundamental for bio-nanotechnology. We present results for how individual mouse fibroblasts from cell line NIH3T3 respond to highly spiked surfaces of silicon...
9.
Micro cantilever movement detection with an amorphous silicon array of position sensitive detectors
Contreras J, Costa D, Pereira S, Fortunato E, Martins R, Wierzbicki R, et al.
Sensors (Basel) . 2011 Dec; 10(9):8173-84. PMID: 22163648
The movement of a micro cantilever was detected via a self constructed portable data acquisition prototype system which integrates a linear array of 32 1D amorphous silicon position sensitive detectors...
10.
A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining
Wierzbicki R, Jonker D, Moore M, Berry S, Loehrer P, Youssoufian H, et al.
Invest New Drugs . 2009 Oct; 29(1):167-74. PMID: 19830388
Purpose: To determine antitumor activity of cetuximab monotherapy in patients with refractory metastatic colorectal carcinoma (mCRC) with lack of specific membrane immunostaining for the epidermal growth factor receptor (EGFR). Patients...